What You Should Know
- Radial has acquired the Management Services Organization (MSO) supporting Mindful Health Solutions, creating the nation’s largest clinical management network dedicated to advanced brain medicine and interventional psychiatry.
- The combined management platform supports 27 outpatient clinics across California, Texas, Washington, and New York, encompassing over 100 clinicians and serving hundreds of thousands of patients with major depressive disorder (MDD), PTSD, OCD, tardive dyskinesia, and suicidality.
- The clinical care model centers on next-generation, evidence-backed brain medicine modalities—including accelerated Transcranial Magnetic Stimulation (aTMS, SWIFT, SAINT), Spravato (esketamine), IV ketamine, fMRI-EEG-guided PRISM, transcranial focused ultrasound (tFUS), and upcoming psychedelic therapeutics (e.g., Comp360 psilocybin)—delivering remission rates up to 79% (compared to 5–30% for traditional SSRI/talk therapy regimens).
Moving Beyond Pill-Based Psychiatry
While conventional outpatient psychiatry has relied heavily on trial-and-error oral SSRIs and psychotherapy since the 1980s, treatment-resistant depression (TRD) and high-acuity psychiatric disorders often see standard remission rates between 5% and 30%. Historically, advanced neuromodulation and rapid-acting therapies have remained siloed in academic medical centers or constrained by out-of-network cash-pay models.
The combined Radial and Mindful Health Solutions network scales access to evidence-backed interventional brain medicine:
- High-Efficacy Interventional Modalities: Deploys rapid-acting therapeutics and neuro-technologies—including accelerated TMS (aTMS), Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), SWIFT protocols, Spravato (esketamine), IV ketamine, fMRI-EEG-guided PRISM, and transcranial focused ultrasound (tFUS)—achieving clinical remission rates as high as 79%.
- RadialOS Decision Intelligence: Implements an AI-guided clinical operating system that pairs longitudinal patient biomarkers, clinical histories, and diagnostic algorithms to match patients with optimal interventional protocols while automating authorization and care coordination workflows.
- National Scaled Infrastructure: Supports over 100 specialized clinicians across 27 outpatient centers, backed by a clinical research foundation comprising more than 368 peer-reviewed published studies and clinical trials.
- In-Network Insurance Integration: Delivers treatments through an insurance-first model across major commercial and government payers, including Medicare, TRICARE, the VA Community Care Network (VA-CCN), Aetna, Cigna, UnitedHealthcare, and Blue Cross Blue Shield plans.
- Neurodegenerative Research & Expansion: Establishes clinical trial pathways to expand neuromodulation protocols beyond behavioral health into neurodegenerative conditions such as Parkinson’s disease.
Leadership Transitions
Clinical and scientific leadership transitions include Dr. Owen Muir, MD serving as Chief Scientific Officer of Radial, Dr. Tobias Marton, MD, PhD serving as Chief Medical Officer for the unified clinical network, Dr. Carlene MacMillan, MD as Chief Product Officer, and John Capecelatro as CEO of Radial; Mindful Health Solutions CEO Mark Kehoe transitions to an advisory role.
“Brain medicine is all we talk about amongst researchers, but lacks mainstream awareness. We’re here to change that. I’ve dedicated my career to studying the broad spectrum of brain medicine treatments. We shouldn’t rely on just ‘pill-based psychiatry’ anymore. Treating the whole patient has a life-changing impact, and we have worked with leading-edge clinicians and a robust clinical network to implement a unique process that is helping thousands of patients transform their lives.”
— Dr. Owen Muir, MD, Co-Founder and Chief Scientific Officer, Radial
